ESR1 mutations were originally reported in a small cohort of metastatic breast cancers in 1997 (ref. 10), and confirmed recently in several larger studies that utilized next-generation sequencing and suggested that such mutations are present in ∼20% of metastatic tissue samples but are generally not found in primary tumour samples11, 12, 13. The gene discussed is ESR1; the disease is breast cancer.